Culture medium induced morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 5, 1997, Pages 317-331

  Perng, Yu Pyng ^a   Lin, Chien Cheng ^a   Perng, Ing Ming ^a   Shen, Yung Chi ^a   Chuang, Cheng Keng ^b   Liao, Shuen Kuei ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Antigen expression; Cell culture; Cytotoxicity; LAK; Medium conditions; Melanoma

Indexed keywords

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CYTOLYSIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOREGULATION; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0031469608     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.317     Document Type: Article

References (38)

1. Aubert C, Rouge F, Galindo JR. Tumorigenicity of human malignant melanocytes in nude mice in relation to their differentiation in vitro. J Natl Cancer Inst 1980;26:1029-1040.
2. Aukerman SL, Fidler J. The heterogeneous nature of metastatic neoplasms: relevant to biotherapy. In: Oldham RK (ed) Principles of Cancer Biotherapy. Raven Press, New York, pp21-47, 1987
3. Bennett DC, Dexter TJ, Ormerod FJ, Hart IR. Increased experimental metastatic capacity of a murine melanoma following induction of differentiation. Cancer Res 1986;46:3239-3244.
4. Correale P, Procopio A, Celio L, Genua G, Coppola V, Pepe S, Normanno N, Vecchio I, Palmieri G, Montagnani S, Tagliaferri P, Bianco AR. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated killer-mediated cytotoxicity. Cancer Immunol Immunother 1992;34:272-278.
5. De Vries JE, Comain S, Rumke P. Cytotoxicity of non-T versus T-lymphocytes from melanoma patients and healthy donors on short- and long-term cultured melanoma cells. Int J Cancer 1974;14:427-434.
6. Dippold WG, Lloyd KO, Li TC, Ikeda H, Oettgen HF, Old LJ. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci 1980;77:6114-6118.
7. Ebbessen P, Hesse J, Bergh T, Capita K, Visfeldt J. Cloning from untreated diploid XC-cells by hypotetraploid cells and altered morphology in vitro growth, electric mobility and cyclic AMP content. Eur J Cancer 1975;11:93-96.
8. Eberle J, Krasagakis K, Garbe C, Orfanos CE. Proliferation and morphology of melanoma cells and benign human melanocytes under varying culture conditions. Melanoma Res 1993;3:107-112.
9. Freshney RI. Culture of Animal Cells, 3rd ed. Wiley-Liss, New York, pp86-88, 1994.
10. Fuller BB, Meyskens FL. Endocrine responsiveness in human melanocytes and melanoma cells in culture. J Nat Cancer Inst 1981;66:799-801.
11. Giacomini P, Natali PG, Ferrone S. Analysis of the interactions between human high-molecular-weight melanoma-associated antigens and monoclonal antibodies to three distinct antigenic determinants. J Immunol 1985;135:696-702.
12. Giuffie L, Schreyer M, Mach JP, Carrel S. Cyclic AMP induces differentiation in vitro of human melanoma cells. Cancer 1987;61:1132-1141.
13. Hearing VJ, Cannon GB, Vieira WD, Mercedes AJ, Kameyama K, Law LW. JB/MS murine melanoma: a new model for studies on the modulation of differentiation and tumorigenic and metastatic potential. Int J Cancer 1988;41:275-282.
14. Hersey P, Jamal O, Henderson C, Zardawi, D'Alessandro G. Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, nevi, primary and metastatic melanoma. Int J Cancer 1988;41:336-343.
15. Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci 1986;83:7893-7897.
16. Kolb CA, Mansfield JM. Effects of theophylline treatment on mouse B16 melanoma cells in vitro. Oncology 1980;37:545-549.
17. Lewko WM, Nayak SK, Hubbard WJ, Thurman GB, Oldham RK. Chemosensitivity testing in tumor acquisition, propagation and preservation program. Mol Biother 1989;1:256-260.
18. Liao S-K, Dent PB, McCulloch PB. Characterization of human malignant melanoma cell lines. I. Morphology and growth characteristics. J Natl Cancer Inst 1975;54:1037-1044.
19. Liao S-K, Kawakubo Y, Smith JW, Singal DP, Wong Y-H. Extent of morphological differentiation of human melanoma cells reflected by HLA-DR antigen profiles. In: Rein R (ed) Molecular Basis of Cancer, Part B. Macromolecular Recognition, Chemotherapy, and Immunotherapy. Alan R. Liss, New York, pp355-366, 1985.
20. Liao S-K, Khosravi MJ, Brown JP, Kwong PC. Difference in cell binding patterns of two monoclonal antibodies recognizing distinct epitopes on a human melanomaassociated antigen. Mol Immunol 1987;24:1-
21. Liao S-K, Kwong PC, McCulloch PB, Dent PB. Relationship of malignant potential to in vitro saturation density of human melanoma cell clones. In: Klaus SN (ed.) Pigment Cell, Vol 5, S. Karger: Basel, pp235-241, 1979.
22. Liao, S-K, Kwong PC, Smith JW, Dent PB, Clark DA. Association of morphological differentiation with enhanced surface antigen expression and susceptibility to natural killer cell lysis in theophylline-treated human melanoma cells. J Biol Resp Modif 1983;2:280-292.
23. Liao S-K, Meranda C, Avner BP, Romano T, Husseini S, Kimbro B, Oldham RK. Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies. Cancer Immunol Immunother 1989;28:77-86.
24. Liao S-K, Perng Y-P, Lee L-A, Chang KSS, Lai G-M, Wong E, Ho Y-S. Newly established MST-1 tumor cell line and tumor-infiltrating lymphocyte culture from a patient with soft tissue melanoma (clear cell sarcoma) and their potential: applications to patient immunotherapy. Eur J Cancer 1996;32A:346-356.
25. Marks A, Petsche D, O'Hanlon D. Kwong PC, Stead R, Dunn R, Baumal R, Liao S-K. S100 protein expression in human melanoma cells: comparison of levels of expression among different cell lines and individual cells in different phases of the cell cycle. Exp Cell Res 1990;187:59-64.
26. McCulloch PB, Dent PB, Hayes PR, Liao S-K. Common and individually specific chromosomal characteristics of cultured human melanomas. Cancer Res 1976;36:398-404.
27. Natali PG, Bigotti A, Cavaliere R, Liao S-K, Taniguchi M, Matsui, Ferrone S. Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. Cancer Res 1985;45:2883-2889.
28. Nayak SK, Dillman RO. Establishment of multiple tumor cell lines from a patient with melanoma, a simple method to control fibroblast growth. Clin Biotechnol 1991;3:237-241.
29. Niles RM, Makarski JS. Control of melanogenesis in mouse melanoma of varying metastatic potential. J Natl Cancer Inst 1978;61:523-526.
30. O'Keefe E, Cuatrecasas P. Cholera toxin minies melanocyte- stimulating hormone in inducing differentiation in melanoma cells. Proc Natl Acad Sci USA 1974;71:2500-2504.
31. Prezioso JA, Wang N, Duty L, Bloomer WD, Gorelik E. Enhancement of pulmonary metastatic formation and γ-glutamyltranspeptidase activity in B16 melanoma induced by differentiation in vitro. Clin Exp Metasatasis 1993;11:263-274.
32. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte-mediated cytotoxicicty against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981;1:51-56.
33. Romsdahl MM, O'Neill PA. Tyrosinase inhibition studies in human malignant melanoma growth in vitro. In: McGovern VJ and Russel P (eds) Pigment Cell. Vol. 1, S Karger: Basel, pp111-117, 1973.
34. Sheppard JR, Koestler TP, Corwin SP, Buscarino C, Doll J, Lester B, Russell G, Greig RG, Poste G. Experimental metastasis correlates with cAMP accumulation in B16 melanoma clones. Nature 1984;308:544-547.
35. Siracky J, Sparrow S, Jones M. Relationship between melanogenesis, proliferative activity and response to chemotherapy of human melanoma xenografts. Neoplasms 1984;31.545-549.
36. Werkmeister JA, Triglia T, Machay IR, Dowling JP, Varigos GA, Morstyn G, Burns GF. Fluctuation in expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody, Leo Mel 3. Cancer Res 1987;47:255-230.
37. Woodruff MFA. Cellular heterogeneity in tumors Br J Cancer 1983;47.589-594.
38. Yeh M-Y, Hellstrom I, Hellstrom KE. Clonal variation in expression of a human melanoma antigen defined by a monoclonal antibody. J Immunol 1981;126:1312-1317.